Nyxoah SA (EBR:NYXH)
Belgium · Delayed Price · Currency is EUR | Market Cap | 160.49M -57.5% |
| Revenue (ttm) | 5.64M +11.0% |
| Net Income | -83.72M |
| EPS | -2.24 |
| Shares Out | 43.03M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 34,211 |
| Average Volume | 44,255 |
| Open | 3.780 |
| Previous Close | 3.735 |
| Day's Range | 3.680 - 3.835 |
| 52-Week Range | 3.680 - 11.150 |
| Beta | 0.65 |
| RSI | 38.77 |
| Earnings Date | Mar 19, 2026 |
About Nyxoah
Nyxoah SA, a medical technology company, develops and commercializes solutions to treat obstructive sleep apnea (OSA). The company’s lead solution comprises Genio system, a CE-Marked, patient-centric, minimally invasive, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. Nyxoah SA was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium. [Read more]
Financial Performance
In 2024, Nyxoah's revenue was 4.52 million, an increase of 3.98% compared to the previous year's 4.35 million. Losses were -59.24 million, 37.1% more than in 2023.
Financial StatementsNews
Nyxoah Announces the Signature of a Memorandum of Understanding with Sheikh Shakhbout Medical City Hospital to Improve OSA Therapy Management and Accelerate Access to Genio in the Middle East
Nyxoah Announces the Signature of a Memorandum of Understanding with Sheikh Shakhbout Medical City Hospital to Improve OSA Therapy Management and Accelerate Access to Genio in the Middle East
Nyxoah Invests In Further Expanding Its Belgian Manufacturing Capacity To Support Its Worldwide Growth
Nyxoah Invests In Further Expanding Its Belgian Manufacturing Capacity To Support Its Worldwide Growth Mont-Saint-Guibert, Belgium – January 21, 2026, 10:05 pm CET / 4:05 pm ET – Nyxoah SA (Euronext B...
Nyxoah SA (NYXH) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Nyxoah SA (NYXH) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Publication relating to transparency notification
REGULATED INFORMATION Publication relating to transparency notification Mont-Saint-Guibert (Belgium), January 12, 2026 , 7:00 am CET / 1:00 am ET – In accordance with article 14 of the Law of May 2, 2...
Nyxoah Announces Issuance of First Tranche of Convertible Bonds
Nyxoah Announces Issuance of First Tranche of Convertible Bonds Mont-Saint-Guibert, Belgium – December 19, 2025, 10:05pm CET / 4:05pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “...
Nyxoah Announces Commercial Launch of Genio® Breakthrough Therapy in the Netherlands
Nyxoah Announces Commercial Launch of Genio® Breakthrough Therapy in the Netherlands First Genio implants successfully performed at OLVG West and Zuyderland hospitals
Publication relating to transparency notifications
REGULATED INFORMATION Publication relating to transparency notifications Mont-Saint-Guibert (Belgium), December 2, 2025 , 10:30 pm CET / 4:30 pm ET – In accordance with article 14 of the Act of 2 May ...
Nyxoah to Participate in the Piper Sandler 37th Annual Healthcare Conference
Nyxoah to Participate in the Piper Sandler 37 th Annual Healthcare Conference
Nyxoah's Genio® Therapy Receives Significant 2026 Medicare Reimbursement Increases Under Final CMS Rule
Nyxoah's Genio® Therapy Receives Significant 2026 Medicare Reimbursement Increases Under Final CMS Rule Assignment to New Technology APC 1580 is positive news for Nyxoah's U.S. commercial rollout by s...
Information on the total number of voting rights and shares
REGULATED INFORMATION Information on the total number of voting rights and shares Mont-Saint-Guibert (Belgium), November 20, 2025 , 10:30 pm CET / 4:30 pm ET – In accordance with article 15 of the La...
Nyxoah SA (NYXH) Q3 2025 Earnings Call Transcript
Nyxoah SA ( NYXH) Q3 2025 Earnings Call November 13, 2025 4:30 PM EST Company Participants Pearson Dennis Olivier Taelman - CEO & Executive Director John Landry - Chief Financial Officer Conference C...
Nyxoah Secures Financing Commitments of up to U.S. $77 Million to Drive U.S. Commercialization of Genio
INSIDE INFORMATION REGULATED INFORMATION Nyxoah Secures Financing Commitments of up to U.S. $77 Million to Drive U.S. Commercialization of Genio Financings are comprised of equity investments, includi...
Nyxoah Reports Third Quarter 2025 Financial and Operating Results
REGULATED INFORMATION Nyxoah Reports Third Quarter 2025 Financial and Operating Results US launch off to a strong start. First commercial Genio implants completed with widespread payer coverage drives...
Nyxoah to Participate in the Stifel 2025 Healthcare Conference
Nyxoah to Participate in the Stifel 2025 Healthcare Conference Mont-Saint-Guibert, Belgium – November 3, 10:05pm CET / 4:05pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH), a medical technology comp...
Nyxoah to Release Third Quarter 2025 Financial Results on November 13, 2025
Nyxoah to Release Third Quarter 2025 Financial Results on November 13, 2025
Nyxoah Announces First U.S. Commercial Patients Implanted with Genio® System
Nyxoah Announces First U.S. Commercial Patients Implanted with Genio® System Early Commercial Launch Demonstrates Strong Physician Demand, Successful Pre-Authorizations, and Widespread Payor Coverage ...
Nyxoah Provides an Update on Expanded Middle East Presence
Nyxoah Provides an Update on Expanded Middle East Presence New Centers in Dubai, Kuwait, and Abu Dhabi Following First Genio® Implant in the Region Earlier in 2025 Mont-Saint-Guibert, Belgium – Septem...
Nyxoah Files Patent Infringement Lawsuit Against Inspire Medical Systems, Inc.
Nyxoah Files Patent Infringement Lawsuit Against Inspire Medical Systems, Inc. Mont-Saint-Guibert, Belgium – September 15, 2025, 10:10pm CET / 4:10pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) an...
Nyxoah SA (NYXH) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
Nyxoah SA (NASDAQ:NYXH) Morgan Stanley 23rd Annual Global Healthcare Conference September 9, 2025 5:35 PM EDT Company Participants Olivier Taelman - CEO & Executive Director Presentation Unknown Anal...
Nyxoah Announces Upcoming Investor Events
Nyxoah Announces Upcoming Investor Events Mont-Saint-Guibert, Belgium – September 2, 2025, 10:30pm CET / 4:30PM ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical t...
Nyxoah: High-Risk High-Reward Medtech To Own
Nyxoah's Genio system received FDA approval, unlocking access to the US market and validating its innovative, patient-friendly OSA treatment. Recent earnings show strong revenue growth but continued l...
Nyxoah SA (NYXH) Q2 2025 Earnings Call Transcript
Nyxoah SA (NASDAQ:NYXH) Q2 2025 Earnings Conference Call August 18, 2025 4:30 PM ET Company Participants John Landry - Chief Financial Officer Olivier Taelman - CEO & Executive Director Pearson Denni...
Nyxoah Reports Second Quarter Financial and Operating Results
REGULATED INFORMATION Nyxoah Reports Second Quarter Financial and Operating Results FDA Approves Genio® System for U.S. Market; Company Begins Commercial Launch Mont-Saint-Guibert, Belgium – August 18...
Nyxoah Announces Preliminary Results for the Second Quarter of 2025
Nyxoah Announces Preliminary Results for the Second Quarter of 2025 Mont-Saint-Guibert, Belgium – August 11, 2025, 7:00am CET / 1:00am ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the ...
Nyxoah Receives Approval from FDA for Genio® System for the Treatment of Obstructive Sleep Apnea
INSIDE INFORMATION REGULATED INFORMATION Nyxoah Receives Approval from FDA for Genio® System for the Treatment of Obstructive Sleep Apnea U.S. Commercialization Officially Launched Mont-Saint-Guibert,...